Architecture briefs, regulatory reads, and market analyses we publish under our own byline. The cadence is slow on purpose — pharma marketers don't need more content; they need fewer, better arguments.
Every piece is signed by a named author. No anonymous "Ephicacy Health Team" posts.
Every claim is sourced. OPDP letters, peer-reviewed literature, public-domain MLR commentary, our own production data — citations live in the footnotes.
We do not publish about generative-AI capabilities in the abstract. We publish about regulated-market production problems and how we're solving them in client engagements.
Cadence is one piece every six weeks. We'd rather publish four good arguments a year than 40 forgettable ones.